Abstract
BackgroundImmune checkpoint blockade with PD-(L)1 antibody has become a new standard of treatment for many cancers for its remarkable clinical responses. But only a minority of cancer patients responded to...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
